Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Return on Sales (2018 - 2025)

Lipocine (LPCN) has disclosed Return on Sales for 10 consecutive years, with 27.81% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales fell 2727.0% year-over-year to 27.81%, compared with a TTM value of 1.27% through Sep 2025, down 72.0%, and an annual FY2024 reading of 0.0%, up 574.0% over the prior year.
  • Return on Sales was 27.81% for Q3 2025 at Lipocine, down from 3.54% in the prior quarter.
  • Across five years, Return on Sales topped out at 118.57% in Q2 2021 and bottomed at 219.28% in Q2 2023.
  • Average Return on Sales over 5 years is 14.96%, with a median of 2.13% recorded in 2023.
  • The sharpest move saw Return on Sales tumbled -21401bps in 2023, then surged 18501bps in 2024.
  • Year by year, Return on Sales stood at 0.78% in 2021, then crashed by -2842bps to 21.52% in 2022, then soared by 133bps to 7.0% in 2023, then crashed by -93bps to 0.51% in 2024, then plummeted by -5549bps to 27.81% in 2025.
  • Business Quant data shows Return on Sales for LPCN at 27.81% in Q3 2025, 3.54% in Q2 2025, and 19.87% in Q1 2025.